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X-linked hypophosphataemia (XLH) is the commonest form of
familial rachitic disease.1 It was first described in 1937 by
Albright et al.2 who coined the term 'Hypophosphatemic
vitamin D resistant rickets'. It is inherited as an X-linked-
dominant trait with the mutant gene (PHEX) being located in
the Xp22.1-22.2 region of the X chromosome.3 The most striking
clinical features of this disorder are growth retardation, lower
limb deformities, hypophosphataemia, and a defect in renal
tubular phosphate reabsorption.4 Affected children generally
have short stature and bowing of lower extremities, whereas
adults may develop osteomalacia, dental disease, and osteo-
arthritis. Although XLH is inherited as an X- linked condition,
some 30% of cases are reported to be the result of sporadic
mutations. The aims of this study were to investigate the
pattern of clinical presentation in a series of South African XLH
subjects with particular reference to ethnic differences, to assess
the inheritance in each case, and lastly, to determine the
perceptions and psychosocial problems associated with the
disease.
Methods
Subjects for the clinical part of the study included those who
attended the clinic held at the Medical Research Council
Mineral Metabolism Research Unit (MMRU) at Chris Hani
Baragwanath Hospital as well as those who consulted the
genetic counselling clinic of the Department of Human
Genetics, National Health Laboratory Services (NHLS) in
Johannesburg. Clinical details of the subjects were collected
either from patient records, or from examination of those
subjects who attended the clinic within the period of this study
(January - December 1998). Altogether 50 subjects (17 males
and 33 females) were investigated. Thirty-one of them were
black, 17 white and 2 Indian. For the genetic part of the study,
the family pedigrees of the subjects were derived from their
records and family histories were taken from those who
attended the clinic to verify their pedigrees. Routine
biochemical investigations in serum (calcium, phosphorus,
total alkaline phosphatase (ALP), intact parathyroid hormone
(iPTH), 25-hydroxy vitamin D (25-OHD) and 1,25-dihydroxy
vitamin D (1,25(OH)2D) and creatinine) and in urine (calcium,
phosphorus and creatinine) were performed in the laboratory
of either the MMRU or the NHLS. Subjects for the psychosocial
part of the study included 20 parents who had a child with
XLH, and 7 subjects (aged 16 years or more) who volunteered
to participate. They were interviewed using a specially
constructed schedule of 21 questions. In addition, a validated
questionnaire on depression (Beck’s Depression inventory)5
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was used to assess depression in subjects. The study was
approved by the Committee for Research on Human Subjects
of the University of the Witwatersrand. Chi-squared and
Fisher's exact tests were used to analyse the data.
Results
The results of the clinical part of the study were collected from
a retrospective analysis of the records available on the 50
subjects (17 males and 33 females) supported by clinical
examination of 26 of those subjects during the study period.
Analysis of the pedigrees of the subjects showed that the
disorder was more common in females than males (the sex
ratio was 2:1), as expected in X-linked-dominant conditions.
The sporadic type of mutation (N = 27, 54%) was slightly but
not significantly more common than the hereditary type (N =
23, 46%). However, sporadic cases tended to be more prevalent
in the black (64%) than the white population (41%) (p = 0.11).
Most of the affected subjects had shown symptoms in early
childhood and the mean age of onset of symptoms of XLH
(according to the parents’ reports) was 2.02 years, with a range
of 0.25 - 10 years. However, the subjects with the hereditary
type of XLH had a significantly earlier reported onset of the
disorder (1.54 ± 0.85 years) than did those with the sporadic
type (2.37 ± 1.75 years) (p = 0.03). The 17 white subjects also
had a significantly earlier reported onset of the disorder (1.4 ±
0.66 years) than the 31 black subjects (2.37 ± 1.7 years) 
(p = 0.04).
The presenting clinical features were lower limb deformities
(80%), short stature (10%), upper limb deformities (20%), rickety
rosary (20%) and abnormal shape of skull (16%) (Table I).
The height for age z-score was significantly different between
the black and white subjects, with white subjects (–2.39 ± 1.07)
being taller than the black subjects (–3.79 ± 1.43). However,
there was no difference between males and females, or between
sporadic and hereditary cases. No significant racial or gender
differences or differences between modes of inheritance were
found for any biochemical test results (Table II). However,
there was a trend for those with the inherited form of the
disease and for whites to have higher serum calcium values 
(p = 0.09 and p = 0.07 respectively).
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Table II.  Biochemical findings (at presentation) in different XLH subgroups (mean ± SD)*
Total Sporadic Inherited p-value Male Female p-value Black Caucasoid p-value
Serum 2.36 ± 2.31 ± 2.42 ± 0.09 2.33  ± 2.37 ± 0.37 2.33 ± 2.42 ± 0.07
total 0.14 0.10 0.15 0.16 0.12 0.12 0.15
calcium (22) (18) (15) (25) (28) (11)
(mmol/l)
Serum 0.89 ± 0.88 ± 0.94 ± 0.20 0.88 ± 0.90 ± 0.72 0.89 ± 0.89 ± 0.99
phos- 0.20 0.16 0.23 0.20 0.20 0.17 0.27
phorus (22) (18) (15) (25) (28) (11)
(mmol/l)
Serum 821 ± 816 ± 829 ± 0.92 785 ± 843 ± 0.65 836 ± 742 ± 0.51
ALP 397 466 298 390 407 386 431
(IU/l) (23) (18) (15) (26) (29) (11)
TRP 73.2 ± 70.0 ± 78.2 ± 0.30 71.9 ± 73.9 ± 0.80 † † †
(%) 19.6 22.8 12.1 18.2 20.9
(16) (10) (10) (16)
*Numbers in parenthesis are the number of subjects included.
†Calculations were not done because there were very few results.
ALP = alkaline phosphatase; TRP = tubular resorption of phosphate.
Table I. Physical deformities at the time of presentation(n = 50)
Number of subjects
before treatment
Physical deformities Number % of total subjects
Lower extremeties
Varus deformities 40 80
Valgus deformities 7 14
Joint abnormalities 4 8
Fracture of femur 2 4
Pelvic deformities 1 2
Ligamental laxity 1 2
Upper extremeties
Widened wrist (splaying) 10 20
Varus deformity of elbow 1 2
Skull
Abnormal shape (e.g. scapho-
cephaly, brachycephaly) 8 16
Frontal bossing 4 8
Spinal deformities 1 2
Chest
Rickety rosary 10 20
Harrison’s sulcus 4 8
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The biochemical features were typical of subjects with XLH
(normal serum calcium, hypophosphataemia, elevated serum
ALP, and reduced tubular reabsorption of phosphate (TRP) and
TmP/GFR (maximum rate of renal tubular reabsorption of
phosphate per litre of glomerular filtration rate) (Table II).  
In spite of medical treatment, 77.7% of the subjects required
corrective orthopaedic surgery. Prolonged hospital admissions
were also associated with this disorder. Only a few subjects
had complications such as tertiary hyperparathyroidism 
(N = 1, 2%) and chronic diarrhoea (N = 4, 8%) associated with
phosphate treatment. One subject had a foot drop following a
corrective tibial osteotomy.
The data for the psychosocial part of the study were
collected using a schedule of questions in an interview with the
parents of 20 subjects and with 7 older subjects (aged 16 years
or more). Analysis of the responses to the interview showed
that parents did not have a clear understanding of the
hereditary nature of XLH before attending a specialised clinic
(Table III), and even after attending such a clinic it was still not
clear to 50% of the parents. Before attending the clinic only 20%
understood the hereditary nature of the disease. Forty-five per
cent of subjects believed that nutritional causes and lack of
sunlight were major contributing factors. 
In the present study, parents were asked if the disorder had
any effect on the child’s relationship with other children. Four
parents (20%) reported that their children had problems with
other children partly due to the physical deformity, inability to
run and short stature associated with XLH. Although parents
described various family problems, only 1 parent stated that
her affected child had a difficult relationship with a sibling
partly due to his physical deformities.
The majority of the parents (N = 17, 85%) stated that they
would like to have prenatal diagnosis of XLH in future, but
only a few of them (N = 2, 10%) would have requested
termination of pregnancy on the basis of a positive result.
Although XLH is not a life-threatening condition, it still
affected the functioning and progress of the subjects and
disrupted their lives (Table IV).
It was also associated with significantly more depression in
mothers than fathers (p = 0.04). Altogether, 60% of the parents
did not have contact with other affected families and 83% of
these parents said that they would like such contact. Finally,
most of the parents (90%) indicated that they would like to join
a support group. 
Discussion
In the cohort there were more females (66%) than males (34%),
as is to be expected in an X-linked-dominant disorder like
XLH. Although the male-to-female ratio in the sporadic cases
was lower (1:1.7) than in the subjects with a family history
(1:2.3), there was no statistically significant difference between
the two groups. Sporadic cases were more common in black
(20/31, 64%) than in white subjects (7/17, 41%), but no
statistically significant difference was found (p = 0.11).
The mean age of onset of XLH in the subjects studied was
2.02 years. This is similar to the age of onset reported by
Carpenter.6 In the present study, the subjects with the inherited
type of XLH had a significantly earlier age of reported onset of
the disorder than did those with the sporadic type. Also, the
white subjects had a significantly earlier age of reported onset
of the disorder than did the black subjects. One possible
explanation is that white subjects might have been identified
earlier than black subjects because of better health awareness
and accessibility of health services (which in the past were
more easily available to the former group). No differences were
found when the age of onset in male and female subjects was
compared.
Although many presented for treatment several years after
the onset of symptoms, 5 parents (who had XLH themselves)
brought their newborn children for assessment. For the whole
group, the mean age of presentation for diagnosis was 4.65
years, with a range of 0.01 - 16 years. The remaining 18 parents,
who were XLH subjects themselves, did not bring their
children for a check-up immediately after birth, but rather
waited till their children started showing features of XLH, such
as bowing of the legs. This was probably because of lack of
knowledge of the hereditary nature of the condition, and
indicates that parents should be made aware of this aspect of
XLH and the possible implications for their children.
Table III. Parents’ initial belief about the causes of XLH
Causes Number %
Heredity 4 20
Not heredity 13 65
Nutrition 6 30
Lack of sunlight 3 15
God 2 10
Witchcraft 1 5
Carrying the child on the back 1 5
Unknown 3 15
Total 20 100
Table IV. Disruption of life of subjects as reported by themselves
Disruption of life Number (%)  
Unable to walk long distances 7 (100)
Regular intake of medicine 7 (100)
Regular visit to the hospital 5 (71.4)
Unable to work 3 (42.8)
Prolonged hospitalisation 3 (42.8)
Short stature 3 (42.8)
Unable to go to school 2 (28.6)
Unattractive appearance 1 (14.2)
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No significant difference in age of presentation was found
between males and females, black and white subjects or
between those with hereditary and sporadic forms of XLH.
This is similar to the findings of the study conducted by Whyte
et al.4 in 1996, who found no difference in age of presentation
between male and female, black and white or hereditary and
sporadic form of XLH.  
The findings of the present study showed that the main
presenting complaints were bowing of the legs (88%), problems
in walking (16%), and short stature (10%). Obviously these
problems motivated the parents to seek medical attention.
Abnormalities of the upper extremities are uncommon7 and
were found only in 2 (4%) of the cases in the present study.
Econs et al.8 mentioned other clinical features such as bone
pain, dental abscess, and abnormalities of the skull (e.g.
scaphocephaly). Dental manifestations in XLH are usually
reported in older children and adult subjects with XLH.9,10 In
the present study, dental problems were present in 8% of the
subjects.
A problem of continuing concern for children with XLH is
that most of them never achieve normal height. However,
several investigators have found that normal growth can be
maintained for long periods through appropriate medical
management.1,6,11  Clinical examination of the subjects in the
present study showed that 52% were below the 5th percentile
of height for age at the time of presentation. Although their
height improved after 1 year of treatment, it was still below
normal. Although the height z-scores were significantly lower
in black than in white subjects (p < 0.01), there was no
difference in height z-scores between the male and female
subjects and those with the hereditary and sporadic forms of
XLH. Explanations for higher height z-score in white subjects
are: (i) that white subjects seek treatment earlier and are more
compliant with treatment because of greater familiarity with
medicines and more accessible health services; and (ii) in
general white subjects are taller than black subjects because of
better socio-economic and nutritional circumstances.
In the present study, serum phosphorus, TRP and TmP/GFR
values were significantly lower than normal at presentation, as
expected in XLH subjects. Statistical analysis showed that
mean serum iPTH and 25-OHD values of the subjects at
presentation were no different from normal. Circulating
1,25(OH)2D levels were also normal in subjects with XLH but
inappropriately so given the ambient hypophosphataemia,
which normally serves to increase circulating levels of this
metabolite.11 In this study, statistical analysis showed that mean
1,25(OH)2D levels of the subjects before onset of treatment
were no different from normal (p = 0.77). Whyte et al.4 failed to
show any evidence that the sex or ethnicity of the subjects
affected the expression of the gene for XLH. They used data for
height, dietary calcium, and numerous biochemical parameters.
They also compared these parameters in subjects with
hereditary or sporadic forms of XLH but found no differences.
They concluded that XLH is a sex-dominated disorder without
any gene dose effect. Similarly, in the present study no
differences in biochemistry (serum calcium (total and ionised),
magnesium, phosphate, ALP, iPTH, TRP and TmP/GFR) were
found between the male and female or black and white
subjects or between those with the hereditary or sporadic
forms of XLH. However, the relatively small numbers of
subjects in each subgroup made statistical testing unreliable. 
Treatment of XLH aims to correct the hypophosphataemia,
improve growth, and reduce the severity of the bone
deformities and resulting limitations on activity. At present,
combined therapy with phosphate and calcitriol or 1α-OHD3 is
the best approach.1,12 The majority of subjects in the present
study were treated with phosphate supplementation and the
vitamin D analogue, 1α-OHD3.  However, poor compliance
(57.5%) with the treatment regimen was a major problem,
particularly in school-going children and subjects from remote
areas. Problems were aggravated by the non-availability of
medicine (as phosphate and 1α-OHD3 were not on the
Essential Drug List) in hospitals without any specialists. The
subjects had to come to an academic hospital to collect the
medicine every month, which presented a major stumbling
block. Only the very few subjects who had medical aid
coverage could afford to get a regular supply of medicine
without attending an academic hospital. The subjects with XLH
were usually seen at the MMRU clinics once every 3 - 6
months. As a result, it was not possible to monitor subjects
regularly. Inclusion of the two drugs necessary for treatment
on the Essential Drug List might be helpful in increasing their
availability in remote areas. The situation is even more
hopeless for subjects outside South Africa, where these drugs
are not available. In this study, 77.7% of the subjects had to
undergo corrective orthopaedic surgery partly because of these
problems. 
The sporadic type of XLH accounted for 54% of the cases in
this study. However it may be difficult in an X-linked condition
to determine whether an isolated case represents a new
mutation or whether the mother has inactivation of an X
chromosome carrying the defective gene and a functioning
normal X chromosome. It is therefore problematic to decide
what the a priori risk is for an isolated case, which may have
resulted from a new mutation or from being transmitted by an
apparently non-affected mother, and what the recurrence risks
for the mother's future children are. In future, molecular
studies might be helpful in this situation.
The findings of this study showed that most of the parents
did not have a clear understanding of the hereditary nature of
the condition before attending a specialised clinic at MMRU or
NHLS. However, even after attending a clinic, this was still not
clear to 50% of the parents. In a study in the USA, Econs et al.8
found that despite the presence of XLH in family members,
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most of the affected individuals had little or no knowledge of
the disease. They concluded that the lack of parental
knowledge might be due to their limited access to medical care,
forgetting that they had been told the diagnosis, or the
physician's failure to make the diagnosis of the disease. These
explanations may also be valid for the subjects in the present
study. In addition, the lack of genetic counselling services
accessible to the subjects and lack of proper referral to available
services might play a role in this regard.
XLH is not a lethal condition and therefore affected children
live with their chronic physical disabilities in the community.
The psychosocial issues, which are associated with chronic
disabilities, would in general apply to XLH. The deformities
associated with XLH and possible stigmatisation of affected
people should be taken into consideration when counselling
subjects and their families.
The majority of the parents (75%) said that the physical
deformities of their children had caused disruption in their
lives and 8 parents (40%) said that their children had problems
at schools. The physical deformities of the children had also
caused disruption in family life. Some problems were
associated with financial issues, such as the need for transport,
and loss of parental income as the child had to be taken to
hospital regularly. Others were associated with disruption of
family dynamics caused by prolonged hospitalisation of the
affected child and the necessary regular visits to hospital.
These problems should be taken into account when planning
intervention programmes for the management of chronic
disorders such as XLH. However, for people facing a future
with the challenge of a physical disability, the pattern of
progression of disability over time may be of significance in the
development of psychological distress.13 It is necessary to
evaluate the quality of life of subjects with XLH by assessing
their material circumstances, and interpersonal and personal
psychosocial wellbeing, so that a better counselling service and
intervention programme for subjects with XLH and their
families can be provided.
Although the nature and severity of a disabling condition are
not the sole determinants of family functioning, the presence of
a disabled child has a significant effect on family members.
This should be taken into consideration while counselling
parents with a child with XLH, and it may be beneficial to
counsel the whole family instead of only one or two members.
In the present study, 4 parents (20%) reported that their
children had problems with other children partly due to the
physical deformity, inability to run and short stature associated
with XLH. These problems could probably be ameliorated by
educating parents and teachers about XLH. 
No study has investigated the psycho-social aspects of XLH
on adult subjects. As subjects grow older, their paediatricians
usually stop treating them and they are taken care of by other
medical practitioners who may not be aware of the problems
associated with XLH subjects. Children with chronic physical
handicaps have been found to be at risk for psychological and
social adjustment problems as they grow older. Role modelling
by successful disabled adults and counselling may assist in
successful transition to adulthood. Also, accurately identifying
in a timely manner those physically handicapped children who
are functioning at clinically significant levels of maladjustment
may aid in preventing further psychosocial morbidity.14,15
The majority of the older subjects interviewed said that they
knew about the hereditary nature of the condition and that
they could pass on the disorder to their children. This
knowledge might be helpful when they have their own
children.
In view of these findings, referral for proper genetic
counselling is necessary for these parents and the older
subjects, and the establishment of a support group should be
considered.
Conclusion
The findings show that South African subjects with XLH have
similar features to the patients in other studies, but there is a
higher prevalence of sporadic mutations in black subjects.
Better counselling and/or referral to both general and genetic
counselling services is needed to improve the understanding of
this condition and its inherited nature and reduce psychosocial
effects among the parents of affected children.
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